Berberine does reduce inflammation, and the evidence is reasonably strong. A meta-analysis of 18 clinical trials covering 1,600 participants found that berberine supplementation significantly lowered three key inflammatory markers: interleukin-6 (IL-6) dropped by 1.18 pg/mL, tumor necrosis factor-alpha (TNF-α) fell by 3.72 pg/mL, and C-reactive protein (CRP) decreased by 1.33 mg/L. These aren’t dramatic numbers on their own, but they reflect meaningful shifts in the kind of chronic, low-grade inflammation linked to metabolic disease, joint problems, and cardiovascular risk.
How Berberine Lowers Inflammation
Berberine works through several overlapping pathways rather than a single mechanism. Its most well-studied action involves activating an energy-sensing enzyme called AMPK while simultaneously blocking a protein complex called NF-κB, which acts as a master switch for inflammatory gene expression. When NF-κB is active, it moves into the cell nucleus and triggers the production of inflammatory molecules. Berberine prevents that migration, effectively turning down the volume on the inflammatory response at its source.
This dual action has downstream effects on immune cells. In lab studies using human blood cells exposed to bacterial toxins, berberine reduced the release of IL-6 protein by about 33% on its own. When combined with red yeast rice, that inhibition jumped to 65%. Berberine also suppressed TNF-α release, though the effect was more pronounced at higher concentrations. Notably, berberine appeared to work primarily at the protein level rather than by altering gene expression, suggesting it may interfere with how inflammatory signals are assembled and released rather than whether the genes for those signals are turned on.
The Gut Connection
One of berberine’s more interesting anti-inflammatory effects happens in the gut. High-fat diets damage the intestinal lining, allowing fragments of bacterial cell walls (called lipopolysaccharides, or LPS) to leak into the bloodstream. This “metabolic endotoxemia” is a well-established trigger for the kind of persistent, whole-body inflammation that drives insulin resistance and weight gain.
Berberine helps on multiple fronts here. It reshapes the gut microbiome in ways that reduce the overall bacterial load producing LPS. It also promotes the release of a gut hormone called GLP-2, which stimulates the growth of intestinal lining cells and helps seal the gut barrier. In rats fed a high-fat diet, six weeks of berberine treatment significantly reduced LPS levels in the blood compared to untreated animals, though levels didn’t return all the way to normal. The result was lower expression of inflammatory markers and fewer immune cells infiltrating fat tissue.
Effects on Metabolic Inflammation
Fat tissue in people with obesity isn’t just an energy store. It becomes an active source of inflammation, pumping out inflammatory molecules and attracting immune cells called macrophages. This chronic, low-grade inflammation in fat tissue is a major driver of insulin resistance.
Berberine directly counteracts this process. In obese mice on high-fat diets, it reduced blood levels of TNF-α and IL-6, suppressed the activation of pro-inflammatory macrophages in fat tissue, and improved both glucose tolerance and insulin sensitivity. These anti-inflammatory effects appear to depend on a protein called SIRT1 in fat tissue. When researchers knocked out SIRT1 in mice, berberine’s ability to suppress inflammation and improve insulin sensitivity was significantly weakened, confirming that this protein is a key part of the mechanism.
A separate meta-analysis focused on metabolic parameters found that berberine supplementation reduced CRP by 0.42 mg/L alongside meaningful reductions in body weight, BMI, and waist circumference. The researchers noted that berberine’s anti-inflammatory action likely plays an indirect role in improving metabolic symptoms by breaking the cycle between fat tissue inflammation and metabolic dysfunction.
Berberine and Joint Inflammation
Animal research suggests berberine may also help with the kind of inflammation seen in rheumatoid arthritis. In rats with collagen-induced arthritis (a standard model for RA), berberine treatment reduced paw redness and swelling, lowered arthritis severity scores, and decreased cartilage damage and synovial inflammation on histological examination. Blood levels of four key inflammatory cytokines (IL-1β, IL-6, IL-17A, and TNF-α) all dropped significantly. Paw thickness began decreasing from the sixth week of treatment, a timeline comparable to methotrexate, the standard pharmaceutical treatment used in the same study.
Berberine also reduced the number of cells involved in bone destruction, suggesting potential for protecting joints from the erosive damage that characterizes RA. These results are promising but come from animal models. No large-scale human trials have tested berberine specifically for arthritis outcomes yet.
How It Compares to Metformin
Berberine and metformin share a surprising amount of overlap. Both activate AMPK, both inhibit NF-κB, and both reduce production of the same inflammatory molecules: IL-1β, IL-6, TNF-α, nitric oxide, and prostaglandin E2. Both have demonstrated the ability to reduce inflammation in intestinal tissue and protect against inflammatory damage to the gut lining. The comparison is relevant because metformin is increasingly recognized not just as a blood sugar drug but as an anti-inflammatory agent, and berberine appears to hit many of the same targets through similar pathways.
Dosage That Showed Results
Clinical trials have typically used berberine in the range of 500 to 1,500 mg per day, often split into two or three doses taken with meals. The meta-analysis of 18 trials found a notable pattern: doses under 1,000 mg per day and treatment durations of less than five weeks were enough to produce significant reductions in IL-6 and TNF-α. This suggests you don’t necessarily need high doses or months of use to see anti-inflammatory effects, though longer use may be needed for metabolic benefits like improved insulin sensitivity.
The Bioavailability Problem
Berberine’s biggest limitation is that your body absorbs very little of it. Standard berberine has low solubility, gets actively pumped back out of intestinal cells by a transporter protein, is partially broken down by gut bacteria before absorption, and is rapidly processed by the liver and kidneys. In lab digestion tests, only about 5.5% of a standard berberine extract ended up in a form available for absorption.
Newer formulations attempt to solve this. A phytosome form that combines berberine with sunflower lecithin, pea proteins, and grape seed extract improved bioavailability substantially. In a pharmacokinetic study with healthy volunteers, this formulation achieved blood levels up to 10 times higher than unformulated berberine on a milligram-for-milligram basis, with measurable increases in absorption starting within 30 to 45 minutes. The higher blood levels were achieved with less than half the berberine content per dose, which could also mean fewer gastrointestinal side effects.
Side Effects and Cautions
The most common side effects are gastrointestinal: nausea, bloating, abdominal pain, diarrhea, or constipation. These tend to be more frequent at higher doses and often improve when berberine is taken with food or when doses are split throughout the day. Berberine interacts with several medications, including cyclosporine (used to prevent organ transplant rejection), and it should not be used during pregnancy, while breastfeeding, or given to infants due to the risk of bilirubin buildup, which can cause brain damage in newborns.